Research peptides and growth-hormone secretagogues, with the evidence stated at the strength it actually has.
01PT-141 (bremelanotide) is the only peptide with phase 3 randomized trial data and FDA approval in the sexual desire space — everything else researchers compare it against is operating on preclinical evidence or early human data at best.
02Peptide therapy spans a wide price range — from roughly $100 per month for tissue-repair compounds to over $1,300 for brand-name GLP-1 weight-loss drugs like Wegovy.
03For men over 40, three peptides dominate the research-grade sleep conversation: DSIP (emideltide), epitalon, and CJC-1295. Of the three, DSIP has the most direct human sleep data, CJC-1295 has the strongest pharmacokinetic profile, and epitalon is the most speculative — but all…
04Visceral fat largely comes back after stopping tesamorelin. The clinical trial data are unambiguous: men who discontinue the protocol regain most of the visceral adipose tissue (VAT) reduction within six months unless they replace the pharmacologic stimulus with something else.
05For a 42-year-old man dealing with creeping visceral fat, slower recovery, and flagging energy, the peptide market offers a dizzying menu — but the evidence narrows the useful options quickly.
06BPC-157 carries the stronger and more internally consistent preclinical evidence base for musculoskeletal repair — more animal models, more tissue types, more mechanistic detail.
07Inject sermorelin 30–60 minutes before sleep, in a fasted state. That single timing decision — aligning the peptide's brief stimulus with the body's largest nocturnal growth hormone pulse — accounts for most of what separates effective research protocols from wasted vials.
08Ipamorelin produces a clean, discrete GH pulse per injection — no meaningful cortisol or prolactin bleed, just selective GHSR-1a activation. The standard effective range is 100–300 mcg per injection, one to three times daily, with the GH response plateauing around 300 mcg per…
09The standard TB-500 research protocol runs 8–12 weeks total, divided into a higher-dose loading phase (4–6 weeks) and a reduced-frequency maintenance phase (4–6 weeks).
10Tesamorelin produces real, measurable visceral fat reduction — but its safety profile carries several risks that researchers and clinicians need to understand before designing protocols.
11Animal research on thymosin beta-4 (Tβ4) — the parent molecule behind TB-500 — maps a consistent, tissue-dependent repair arc: measurable molecular activity within hours, functional gains by weeks two to four, and structural consolidation by weeks eight to twelve.
12Ipamorelin triggers a sharp, selective GH pulse via the ghrelin receptor; sermorelin mimics endogenous GHRH to produce a more physiologic, feedback-regulated GH release.
13Researchers working with BPC-157 typically use 250–500 mcg per day, administered subcutaneously, for cycles of four to eight weeks. The evidence base supporting that range is almost entirely preclinical — robust in rodent models, thin in humans — so every number here should be…
14BPC-157 is the stronger candidate for tendon, ligament, and gut repair; TB-500 excels at wound closure, cell migration, and — based on full thymosin beta-4 trials — cardiac tissue protection.
15Semaglutide is the active molecule; Ozempic is one branded product that contains it. The two terms are not interchangeable — and that distinction has real consequences for dosing, insurance coverage, and whether the vial you're buying is FDA-regulated.
16Combining BPC-157, TB-500, and GHK-Cu into a single research protocol is the most common multi-peptide stack in the regenerative space right now — and for good reason.
17Tirzepatide (Mounjaro) produces greater weight loss than semaglutide (Ozempic) in men managing both type 2 diabetes and obesity — and the gap is large enough to matter clinically.
18For most men with obesity-related low testosterone, semaglutide (Ozempic, Wegovy) raises testosterone rather than suppressing it — by attacking the metabolic root cause of functional hypogonadism.
19The short answer: Ozempic carries a boxed FDA warning about thyroid C-cell tumors based on rodent data, but human evidence does not currently show a clear, clinically significant increase in thyroid cancer risk for most patients.
20Semaglutide activates GLP-1 receptors throughout the brain, and the evidence cuts two ways: observational data consistently link it to lower dementia risk, while the phase 3 EVOKE trials found no benefit in established Alzheimer's disease — and a real subset of patients report…
21Lower-dose semaglutide genuinely reduces the frequency of nausea, vomiting, and other GI side effects — but it does not meaningfully lower the risk of the serious adverse events most people are actually worried about.
22Most people who stop semaglutide regain roughly two-thirds of their lost weight within a year — but that outcome is not inevitable if you plan the exit strategically. The biology is real, the risk is quantifiable, and the mitigation strategies exist.
23Nausea and vomiting are the most common reasons people struggle with Wegovy — but they're also largely preventable with the right titration and dietary strategy.
24Yes, BPC-157 can be taken orally and research suggests it remains stable in gastric acid, making oral administration a viable alternative to injectable forms for many therapeutic applications, though bioavailability may differ between routes.
One email a week. The research, not the hype.
What we published, what changed in the evidence, and what it means if you are on a protocol.
No spam, no selling your address. Unsubscribe in one click.
Run the numbers first
43 free calculators — dosing, cost per month, unit conversions. No email required.